Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.
An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press.
After nearly three decades of reviewing NCI-funded extramural projects and sometimes saving NCI from its own folly, the Board of Scientific Advisors has been terminated as part of the Trump administration’s drive to reduce the size of the federal government.
In the starkest opposition yet by Republicans to the Trump administration’s attacks on HHS agencies, senators from both parties sounded an alarm about the damage being done to biomedical research in the U.S.
“We stand at the edge of discovery, and on the brink of losing it,” said Patricia M. LoRusso, the 2024-2025 president of the American Association for Cancer Research. “I believe this is the most scientifically promising moment in the history of cancer research.”